Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.02 and traded as high as $2.00. Cortexyme shares last traded at $1.85, with a volume of 168,423 shares trading hands.
Cortexyme Stock Up 0.5 %
The business’s 50 day moving average is $1.57 and its 200 day moving average is $1.02. The company has a market cap of $55.78 million, a P/E ratio of -0.62 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
- Five stocks we like better than Cortexyme
- The 3 Best Fintech Stocks to Buy Now
- Micron Stock Under $100: Seize the AI-Driven Upside
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- How Investors Can Find the Best Cheap Dividend Stocks
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
